Home › Trials › NCT07392190

Eloralintide for people with persistent obesity on weekly incretin therapy

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

Phase 3 Interventional Eli Lilly and Company · NCT07392190

This trial will test whether adding eloralintide helps adults with persistent obesity or overweight who are already taking a weekly incretin medication, with or without type 2 diabetes.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment900 (estimated)
Ages18 Years and up
SexAll
SponsorEli Lilly and Company Industry-sponsored
Locations178 sites (Birmingham, Alabama and 177 other locations)
Trial IDNCT07392190 on ClinicalTrials.gov

What this trial studies

Adults who remain overweight or obese despite stable weekly incretin therapy will receive either eloralintide or a matching placebo in addition to their background medication and will be followed for about 80 weeks. The study compares weight outcomes and safety between the eloralintide and placebo groups while participants maintain a stable incretin regimen. Eligibility focuses on BMI thresholds (≥30 kg/m2, or ≥27 kg/m2 with an obesity-related complication) and a stable body weight prior to enrollment. People with recent or planned surgical or device-based obesity treatments, type 1 diabetes, or recent disallowed antihyperglycemic medications are excluded.

Who should consider this trial

Good fit: Adults with persistent obesity or overweight (BMI ≥30 kg/m2, or ≥27 kg/m2 with an obesity-related complication) who are on stable weekly incretin therapy and have had less than 5% weight change recently are ideal candidates.

Not a fit: People with type 1 diabetes, recent or planned bariatric or device-based obesity procedures, or recent use of disallowed antihyperglycemic drugs are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, eloralintide could provide additional weight loss and improve obesity-related health measures when added to weekly incretin therapy.

How similar studies have performed: Other amylin receptor agonists, particularly when combined with GLP-1–based therapies, have shown promising weight-loss results in earlier-stage trials.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Are on stable incretin therapy at screening
* With persistent obesity or overweight defined as:

  * ≥30 kg/m2 OR
  * ≥27 kg/m2 with at least one existing obesity related complication at screening:

    * hypertension
    * dyslipidemia
    * obstructive sleep apnea
    * cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
    * type 2 diabetes
* Have a stable body weight (\<5% body weight change) at screening

Exclusion Criteria:

* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
* Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
* Have type 1 diabetes
* Have taken any of the following antihyperglycemic medications within 90 days before screening:

  * dipeptidyl peptidase-4 (DPP-4) inhibitors
  * amylin analogs
  * insulin
* Have had within 90 days prior to screening:

  * heart attack
  * stroke
  * coronary artery revascularization
  * unstable angina, or
  * hospitalization due to congestive heart failure
* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

Where this trial is running

Birmingham, Alabama and 177 other locations

+128 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions OverweightObesityAmylin receptor agonist
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.